CsD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2

被引：50

作者：

Chen, Taoliang ^{[1
]}

Chen, Jiansheng ^{[1
]}

Zhu, Yubo ^{[1
]}

Li, Yan ^{[1
]}

Wang, Yun ^{[1
,2
]}

Chen, Huajian ^{[1
]}

Wang, Jihui ^{[1
]}

Li, Xiao ^{[1
]}

Liu, Yang ^{[1
]}

Li, Baisheng ^{[1
,3
]}

Sun, Xinlin ^{[1
]}

Ke, Yiquan ^{[1
]}

机构：

[1] Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China

[2] Xinjiang Med Univ, Hosp 1, Dept Neurosurg, Urumqi 830054, Peoples R China

[3] Huizhou Cent Peoples Hosp, Dept Neurosurg, Huizhou 516001, Peoples R China

来源：

ONCOGENE | 2019年 / 38卷 / 08期

关键词：

MACROPHAGE SCAVENGER RECEPTOR; PROTEIN-KINASE; HUMAN GLIOBLASTOMA; CANCER; CD163; EXPRESSION; BRAIN; CK2; ANTIGEN; CD133;

D O I：

10.1038/s41388-018-0515-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Glioma is a devastating cancer with a dismal prognosis and there is an urgent need to discover novel glioma-specific antigens for glioma therapy. Previous studies have identified CD163-positive tumour cells in certain solid tumours, but CD163 expression in glioma remains unknown. In this study, via an analysis of public datasets, we demonstrated that CD163 overexpression in glioma specimens correlated with an unfavourable patient prognosis. CD163 expression was increased in glioma cells, especially primary glioma cells. The loss of CD163 expression inhibited both cell cycle progression and the proliferation of glioblastoma multiforme (GBM) cell lines and primary glioma cells. CD163 interacted directly with casein kinase 2 (CK2) and CD163 silencing reduced AKT/GSK3 beta/beta-catenin/cyclin D1 pathway activity via CK2. Moreover, CD163 was upregulated in CD133-positive glioma stem cells (GSCs), and CD163 downregulation decreased the expression of GSC markers, including CD133, ALDH1A1, NANOG and OCT4. The knockdown of CD163 impaired GSC stemness by inhibiting the CK2/AKT/GSK3 beta/beta-catenin pathway. Finally, a CD163 antibody successfully induced complement-dependent cytotoxicity against glioma cells. Our findings indicate that CD163 contributes to gliomagenesis via CK2 and provides preclinical evidence that CD163 and the CD163 pathway might serve as a therapeutic target for glioma.

引用

页码：1183 / 1199

页数：17

共 58 条

[1] Immune Escape Mechanisms as a Guide for Cancer Immunotherapy [J].